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Background:While morbidity attributable to podoconiosis is relatively well studied, its pattern of mortality has
not been established.
Methods: We compared the age-standardised mortality ratios (SMRs) of two datasets from northern Ethiopia:
podoconiosis patients enrolled in a 1-y trial and a Health and Demographic Surveillance System cohort.
Results: The annual crude mortality rate per 1000 population for podoconiosis patients was 28.7 (95% con-
fidence interval [CI] 17.3 to 44.8; n=663) while that of the general population was 2.8 (95% CI 2.3 to 3.4;
n=44 095). The overall SMR for the study period was 6.0 (95% CI 3.6 to 9.4).
Conclusions: Podoconiosis patients experience elevated mortality compared with the general population and
further research is required to understand the reasons.
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Introduction
Many of the neglected tropical diseases (NTDs) listed for elim-
ination, including soil-transmitted helminthiases, schistosomia-
sis, lymphatic filariasis (LF), onchocerciasis and trachoma, are
thought of as disabling rather than the direct causes of excess
mortality. Disability-adjusted life years (DALYs) estimates for
these diseases are predominantly influenced by years lived with
disability rather than years of life lost, although this may reflect
the absence of data onmortality rather than data on the absence
of mortality.1
Podoconiosis, a non-infectious, geochemical NTD charac-
terised by lymphoedema, is associated with severe social, eco-
nomic, physical and mental health consequences.2 Acute der-
matolymphangioadenitis (ADLA) attacks, similar to those in LF
patients, occur at least monthly among untreated patients.3
Stigma results in the inability to marry, divorce among those
alreadymarried, exclusion from school and ostracism in the com-
munity. Disability causes a productivity loss of 45% of work-
ing days per year on average, and depression is common.2 No
information on mortality has yet been reported, although anec-
dotal evidence suggests increased mortality related to acute
attacks.
We compared mortality in a group of podoconiosis patients
enrolled in a clinical trial with that in a local general population
cohort. Podoconiosis patient data were obtained from the com-
pleted Gojjam Lymphoedema Best Practice Trial (GoLBeT).4 In
brief, this trial tested the effectiveness of a simple lymphoedema
self-care package in reducing the incidence of ADLA among
podoconiosis patient participants who were followed up over a
12-month period. This took place in the Aneded woreda (district)
of Amhara region, 278 km northwest of Ethiopia’s capital Addis
Ababa and 260 km from Bahir Dar, Amhara’s regional capital.
GoLBeT mortality rates were standardised against those of the
Dabat Health and Demographic Surveillance System (HDSS), a
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits








h/article/114/12/1035/6000683 by guest on 08 M
arch 2021
H. Masraf et al.
Table 1. A summary of the age-adjusted annual mortality data and the associated SMRs for the GoLBeT and Dabat HDSS datasets
Annual mortality rate per 1000 population (95% CI)
Age group (years) Dabat HDSS GoLBeT SMR (95% CI)
18–30 0.86 (0.56 to 1.25) 14.29 (0.36 to 79.59) 16.69 (0.42 to 93.00)
31–40 1.21 (0.68 to 2.00) 26.79 (5.52 to 78.28) 22.11 (4.56 to 64.62)
41–50 2.42 (1.46 to 3.78) 25.16 (6.86 to 64.42) 10.38 (2.83 to 26.57)
51–60 3.33 (2.00 to 5.19) 36.59 (13.43 to 79.63) 10.99 (4.03 to 23.93)
61–70 7.52 (4.95 to 10.94) 18.35 (2.22 to 66.28) 2.44 (0.30 to 8.81)
≥71 24.99 (19.45 to 31.63) 61.22 (12.62 to 178.92) 2.46 (0.51 to 7.16)
vital event registration system in the Dabat district of Amhara,
821 km northwest of Addis Ababa.5
Methods
The GoLBeT dataset and the Dabat HDSS were retrospectively
analysed using data from a 17-month period (28 February 2015–
30 July 2016) to ensure comparability. The Dabat HDSS was
selected as the reference population, representing the Amhara
region’s general population, as it shares sociodemographic char-
acteristics with the GoLBeT and, like Aneded, Dabat’s economy
relies on subsistence farming.
Demographic data including age, sex, and family-reported
date of death were used in this analysis. Data from outside of
the 17-month study period and people with incomplete demo-
graphic data and <18 y of age were excluded, thus aligning this
with the GoLBeT inclusion, exclusion and withdrawal criteria.
Data analysis was performed with SPSS version 25.0 (IBM,
Armonk, NY, USA). The age distributions of both populations were
descriptively analysed and compared using a two-tailed Mann–
Whitney U test. The crude and age-standardised mortality rates
were calculated and expressed per 1000 population, using the
total number of deaths in the population as the numerator and
the total population size as the denominator. The Dabat HDSS
mortality rates were then annualised. The 95% confidence inter-
vals (CIs) for the annual crude and age-adjusted rates were
calculated using the Poisson distribution. SMRs were calculated
using indirect standardisation. CIs for the SMRs were obtained
using Fisher’s exact test, due to the small expected number of
deaths.
Results
A total of 696 people were randomised to immediate or delayed
treatment arms in the GoLBeT. However, 33 withdrew before
completion or lacked adequate data fromwhich to computemor-
tality rates and were excluded.4 Thus a total of 663 participants
were included: 344males (51.9%) and 319 females (48.1%) with
a median age of 50.0 y (interquartile range [IQR] 40.0–60.0).
The Dabat dataset contained 229 484 entries for 88 041 indi-
viduals. Once the inclusion/exclusion criteriawere applied, 44 095
individuals were suitable for analysis: 20 927 males (47.5%) and
23 168 females (52.5%). The median age was 31.0 y (IQR 23.0–
45.0). The age distributions in the datasets differed, with the GoL-
BeT population being older (p<0.001), but the sex distributions
were similar, with a 4.4% difference. For full demographic data
see Supplementary Table 1.
There were 19 deaths in the GoLBeT population and 175
deaths in the Dabat HDSS. The crude annual mortality rate for
the GoLBeT dataset was 28.66 (95% CI 17.25 to 44.75) per 1000
population, while that of the general population was 2.79 (95%
CI 2.27 to 3.39) per 1000 population. The crude mortality rate
ratio (MRR) was 10.26 (95% CI 3.00 to 35.05), indicating over-
all excessmortality among podoconiosis patients compared with
the general population. When adjusting for age, the annual mor-
tality rate for the GoLBeT population was 22.45 (95% CI 12.56
to 37.02) per 1000 population. Age-adjusted SMRs further sug-
gest higher mortality rates among all ages of adult podoconiosis
patients (Table 1). The overall SMR for the study period was 5.99
(95% CI 3.61 to 9.36). The SMR for those ≤60 y of age was 12.42
(95% CI 6.79 to 20.84) and the SMR for those >60 y was 2.45
(95% CI 0.79 to 5.70).
The age-adjusted SMRs provided very strong evidence for dif-
ferences in mortality between populations in the 31–40, 41–50
and 51–60 y groups and no strong evidence for differences in the
18–30, 61–70 or ≥71 y age groups. This suggests that podoco-
niosis contributes to mortality, directly or indirectly. We found
no evidence for trends in mortality by either disease stage or
income, but numbers in the GoLBeT dataset were small. Podoco-
niosis patients may suffer sepsis secondary to adenolymphan-
gitis or podoconiosis could interact with underlying comorbidi-
ties. Of the podoconiosis patients studied, the most common
perimortem signs and symptoms included a feeling of weak-
ness (31.6%), generalised swelling (26.3%), jaundice (15.8%) and
difficulty breathing/shortness of breath (15.8%). Some of these
signs are indicative of sepsis and/or organ damage, but without
autopsy data this cannot be confirmed. The high prevalence of
mental health disorders and poverty among patients might also
be implicated in mortality.
Our study had a number of limitations. Both populations
used family-reported dates of death, which could have intro-
duced recall bias. The number of deaths in the GoLBeT dataset
was small, making further mortality modelling adjustments
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differences in mortality between the datasets unrelated to
podoconiosis.
Conclusions
This study provides evidence that podoconiosis patients experi-
ence greater mortality than the general population in northern
Ethiopia. If such an observation is confirmed in future studies,
this will have important implications for our understanding of the
global DALYs burden of podoconiosis, its impact on the health of
individuals and the benefits on mortality of scaling up morbidity
management programmes.
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